Literature DB >> 2025577

Interleukin-6 and interleukin-1 enhancement of GM-CSF-dependent proliferation of haematopoietic progenitor cells in myelodysplastic syndromes.

M R Schipperus1, P Sonneveld, J Lindemans, K van Lom, M Vlastuin, J Abels.   

Abstract

Interleukin-1 (Il-1) and Interleukin-6 (Il-6) have been reported to enhance the growth factor dependent colony formation of normal primitive haematopoietic progenitor cells as well as of leukaemic blast-cell progenitors. We investigated the effects of Il-1 beta and Il-6 in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) on the in vitro colony formation of myeloid progenitors from 23 patients with a myelodysplastic syndrome (MDS). Neither Il-1 beta nor Il-6 were found to have colony stimulating activity on their own. In normal bone marrow cultures, either stimulated with optimal or suboptimal doses of GM-CSF, no enhancing or antagonistic effect of Il-6 or Il-1 beta was detected. In a majority of the MDS cases, however, an enhancing effect of Il-6 and Il-1 beta in combination with GM-CSF was observed (20/23 and 10/21 cases respectively). In three cases of the Il-6 and GM-CSF combination an antagonistic effect was observed as well as in four cases of the Il-1 beta and GM-CSF combination. A delayed addition of Il-6 to the cultures did not result in an abrogation of the effect, indicating that Il-6 is not required immediately at the initiation of the culture. These results indicate that costimulation with Il-6 or Il-1 beta is able to augment the GM-CSF activity on MDS myeloid progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2025577     DOI: 10.1111/j.1365-2141.1991.tb08619.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.

Authors:  Daniel A Pollyea; Chelsea Harris; Jennifer L Rabe; Brenna R Hedin; Lesly De Arras; Sigrid Katz; Emily Wheeler; Rafael Bejar; Matthew J Walter; Craig T Jordan; Eric M Pietras; Scott Alper
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

Review 2.  Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.

Authors:  Kathryn S Ivy; P Brent Ferrell
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

Review 3.  Bone Marrow Immunity and Myelodysplasia.

Authors:  Claude Lambert; Yuenv Wu; Carmen Aanei
Journal:  Front Oncol       Date:  2016-07-20       Impact factor: 6.244

4.  Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias.

Authors:  Mahesh Raundhal; Shrestha Ghosh; Samuel A Myers; Michael S Cuoco; Meromit Singer; Steven A Carr; Sushrut S Waikar; Joseph V Bonventre; Jerome Ritz; Richard M Stone; David P Steensma; Aviv Regev; Laurie H Glimcher
Journal:  Nat Immunol       Date:  2021-03-22       Impact factor: 25.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.